Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1863259

Multiple Myeloma - Pipeline Review, Q3 2011

Description:

Multiple Myeloma - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Multiple Myeloma - Pipeline Review, Q3 2011', provides an overview of the Multiple Myeloma therapeutic pipeline. This report provides information on the therapeutic development for Multiple Myeloma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Myeloma. 'Multiple Myeloma - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Multiple Myeloma.
- A review of the Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Multiple Myeloma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Multiple Myeloma pipeline depth and focus of Multiple Myeloma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Multiple Myeloma Overview
Therapeutics Development
Multiple Myeloma Therapeutics under Development by Companies
Multiple Myeloma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Multiple Myeloma Therapeutics - Products under Development by Companies
Multiple Myeloma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Multiple Myeloma Therapeutics Development
Multiple Myeloma - Therapeutics Assessment
Late Stage Drug Profiles
Multiple Myeloma Therapeutics – Drug Profile Updates
Multiple Myeloma Therapeutics - Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Multiple Myeloma, Q3 2011
Products under Development for Multiple Myeloma – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Bristol-Myers Squibb Company, 2011
Johnson & Johnson, 2011
F. Hoffmann-La Roche Ltd., 2011
Kyowa Hakko Kirin Co., Ltd., 2011
Abbott Laboratories, 2011
Eli Lilly and Company, 2011
Viralytics Ltd., 2011
GlaxoSmithKline plc, 2011
Seattle Genetics, Inc., 2011
Genentech, Inc., 2011
Gilead Sciences, Inc., 2011
Biotest AG, 2011
Merck & Co., Inc., 2011
AbGenomics International, Inc., 2011
Micromet, Inc., 2011
Infinity Pharmaceuticals, Inc., 2011
Takeda Pharmaceutical Company Limited, 2011
BioSante Pharmaceuticals, Inc., 2011
ZIOPHARM Oncology, Inc., 2011
Millennium Pharmaceuticals, Inc., 2011
Novartis AG, 2011
Cephalon, Inc., 2011
Human Genome Sciences, Inc., 2011
ImmunoGen, Inc., 2011
Pfizer Inc., 2011
Sigma-Tau S.p.A., 2011
Sunesis Pharmaceuticals, Inc., 2011
Genmab A/S, 2011
Astex Therapeutics Limited, 2011
Cyclacel Pharmaceuticals Inc., 2011
Celgene Corporation, 2011
Onyx Pharmaceuticals, Inc., 2011
Incyte Corporation, 2011
Geron Corporation, 2011
MannKind Corporation, 2011
4SC AG, 2011
EntreMed, Inc., 2011
GENTIUM S.p.A., 2011
Celldex Therapeutics, Inc., 2011
AEterna Zentaris Inc., 2011
ImmunoCellular Therapeutics, Ltd., 2011
IMMUNOMEDICS, INC, 2011
Avalon Pharmaceuticals, Inc., 2011
Cleveland BioLabs, Inc., 2011
Oncolytics Biotech Inc., 2011
Compugen Ltd., 2011
Alexion Pharmaceuticals, Inc., 2011
Telik, Inc., 2011
TopoTarget A/S, 2011
CytRx Corporation, 2011
Oncogenex Pharmaceuticals, Inc., 2011
Pharmacyclics, Inc., 2011
Array BioPharma Inc., 2011
XOMA Ltd., 2011
MorphoSys AG, 2011
BioInvent International AB, 2011
Senesco Technologies, Inc., 2011
Threshold Pharmaceuticals, Inc., 2011
CrystalGenomics, Inc., 2011
Innate Pharma SA, 2011
Piramal Life Sciences Limited, 2011
SymBio Pharmaceuticals Limited, 2011
The Vanderbilt-Ingram Cancer Center, 2011
Debiopharm Group, 2011
Chroma Therapeutics Ltd., 2011
Avaris, 2011
Abiogen Pharma S.p.A., 2011
Acceleron Pharma, Inc., 2011
Aquinox Pharmaceuticals Inc., 2011
Arno Therapeutics, Inc., 2011
Vaccinex, Inc., 2011
CanBas Co., Ltd., 2011
NovImmune SA, 2011
CyDex Pharmaceuticals, Inc., 2011
Axelar AB, 2011
Immune System Therapeutics Ltd., 2011
Xencor, Inc., 2011
Acetylon Pharmaceuticals, Inc., 2011
PharmaMar, S.A., 2011
Bellicum Pharmaceuticals, Inc., 2011
AB Science, 2011
Biokine Therapeutics Ltd., 2011
Cylene Pharmaceuticals, Inc., 2011
GlycoMimetics, Inc., 2011
Nereus Pharmaceuticals, Inc., 2011
AVEO Pharmaceuticals, Inc., 2011
EUSA Pharma, Inc., 2011
TAU Therapeutics, LLC, 2011
Immunovative Therapies, Ltd., 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Multiple Myeloma Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Multiple Myeloma, Q3 2011
Products under Development for Multiple Myeloma – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Discovery and Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1863259

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Wednesday, June 19, 2013
7:30:57 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Multiple Myeloma - Pipeline Review, Q3 2011

Web Address

http://www.researchandmarkets.com/reports/1863259

Office Code

OC8DIQQMQRQOPR

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EUR 382
Electronic (PDF) - Site License		EUR 765
Electronic (PDF) - Enterprisewide		EUR 1,147

Contact information

Please enter all the information below in block capitals.

                    Title:
                
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                    First Name:
                
                    Last Name:
                    
                    Email Address:
                
                    Job Title:
                
                    Organisation:
                
                    Address:
                
                    City:
                
                    Postal / Zip Code:	
                
                    Country:	
                
                    Phone Number:	
                
                    Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Wednesday, June 19, 2013
7:30:57 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

Multiple Myeloma - Pipeline Review, Q3 2011

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)